Toleranzia bedriver forskning och utveckling av läkemedel för behandling av autoimmun sjukdom.

Quotes for Toleranzia AB

Right Now

+/-
0,40
%
10,70%
Latest
4,14
High
4,14
Low
3,80
Volume
39 236
Turnover (SEK)
154 303
Value (MSEK)
64,3

Board

CEO

  • Charlotte Fribert

Chairman Of The Board

  • Ola Rönn

Board

  • Ola Rönn
  • Kristian Sandberg
  • Anders Waas
  • Maarten Kraan
  • Eva Lindgren
  • Anders Milton

Videos

Largest Owner

Name Capital % Votes % Date
GU Ventures 13,58 13,58 2018-06-30
Robert Joki 10,37 10,37 2018-06-30
Leo Christoffer Graf 7,43 7,43 2018-06-30
Avanza Pension 7,07 7,07 2018-06-30
Loni Medicals AB 6,15 6,15 2018-06-30
Gunvald Berger 4,06 4,06 2018-06-30
Sören Christensen 3,32 3,32 2018-06-30
Formue Nord Markedsneutral A/S 2,14 2,14 2018-06-30
Johan Tilander 2,04 2,04 2018-06-30
Nordnet Pensionsförsäkring 1,93 1,93 2018-06-30
** Holdings by Modular Finance AB. Compiled and processed data from various sources, including Euroclear, Morningstar and the Swedish Financial Supervisory Authority.

Key Numbers

  3/31/2018 12/31/2017 9/30/2017 6/30/2017 3/31/2017 12/31/2016 9/30/2016
Number of months that the report spans Q1 3 Months Q4 3 Months Q3 3 Months Q2 3 Months Q1 3 Months Q4 3 Months Q3 3 Months
Total revenue 0.95 0.82 0.50 0.84 0.76 1.05 0.86
Earnings before interest and tax -1.43 -1.56 -0.90 -1.59 -1.35 -1.82 -1.03
Profit before tax -1.43 -1.57 -0.90 -1.59 -1.32 -1.83 -1.00
Net profit -1.43 -1.57 -0.90 -1.59 -1.32 -1.83 -1.00
Earnings per share -0.09 -0.2 -0.11 -0.2 -0.17 -0.23 -0.06
Dividend per share
Equity 31.81 14.67 16.24 17.14 18.73 20.06 21.22
Fixed assets 10.20 9.26 8.47 7.95 7.26 6.70 5.82
Intangible assets
Current assets 26.19 7.52 9.64 11.32 13.32 15.59 17.76
Total asset 36.39 16.77 18.11 19.27 20.59 22.28 23.58
Long term liabilities 0.96 0.98 1.00 1.01 1.03 1.04 1.06
Current liabilities 3.61 1.13 0.87 1.12 0.82 1.18 1.30
Number of shares (st) 15 534 170 7 992 814 7 992 814 7 992 814 7 992 814 7 992 814 7 902 000

Upcoming reports

  • 2019-02-21 Year End Report

  • 2018-11-16 Interim Report Q3

  • 2018-08-24 Half Year Report